skip to content


Issue No. 8 | February 24, 2012

News and Features

AIDSinfo Offers User-Friendly Clinical Trials Search

If you are interested in participating in an HIV/AIDS-related clinical trial or just want to learn more about ongoing or completed trials, AIDSinfo can help! Our AIDSinfo and infoSIDA clinical trials search tools offer quick access to more than 80 formatted searches predesigned to search for HIV/AIDS-related clinical trials in specified areas of HIV/AIDS-related research. The search tools can quickly link you to HIV/AIDS-related trials pertaining to cancer; coinfections; complications/side effects; opportunistic infections; and prevention, treatment, and vaccine research. The search tools can also help you easily locate trials relevant to specific populations or age groups. 

If you prefer to customize your own trial search, use our clinical trials advanced search function. The advanced search function provides you with many options to refine your search including by keyword, recruitment status, location, and trial phase.

AIDSinfo health information specialists are available by phone (800-448-0440) or Live Chat to assist you with your clinical trials search.

Study Suggests Tenofovir Exposure Is Associated with Increased Risk of Kidney Disease in People Infected with HIV

“Despite widespread highly active antiretroviral therapy use, HIV disease remains associated with increased risk of kidney disease. Whether tenofovir use is associated with higher risk of kidney disease is controversial. …

“[Study researchers] evaluated the association of cumulative and ever exposure to tenofovir on kidney outcomes in 10,841 HIV-infected patients from the Veterans Health Administration who initiated antiretroviral therapy from 1997-2007. …

“Cox proportional hazards and marginal structural models evaluated associations between tenofovir and time to first occurrence of 1) proteinuria (two consecutive urine dipstick measurements ≥30mg/dL), 2) rapid decline in kidney function (≥3ml/min/1.73m annual decline), and 3) CKD (estimated glomerular filtration rate<60 ml/min/1.73m). …

“Median follow-up ranged from 3.9 years (proteinuria) to 5.5 years (CKD), during which 3400 proteinuria, 3078 rapid decline, and 533 CKD events occurred. After multivariable adjustment, each year of exposure to tenofovir was associated with 34% increased risk of proteinuria (95%CI 25-45%, p<0.0001), 11% increased risk of rapid decline (3-18%, p=0.0033), and 33% increased risk of CKD (18-51%; p<0.0001). Pre-existing renal risk factors did not appear to worsen the effects of tenofovir. Other ARVs showed weaker or inconsistent associations with kidney disease events. Among those who discontinued tenofovir use, risk of kidney disease events did not appear to decrease during follow-up. …

“Tenofovir exposure was independently associated with increased risk for three types of kidney disease events, and did not appear to be reversible. Because subtle kidney function decline affects long-term morbidity and mortality, the balance between efficacy and probable adverse effects requires further study.”

More information is available: